Gastro-Intestinal Tolerance
Conditions
Brief summary
The objective of this study is to capture information on gastrointestinal tolerance (GI) of an oral nutritional supplement containing a new protein blend in healthy children aged ≥ 3 to ≤ 10 years.
Interventions
Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
Sponsors
Abbott Nutrition
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 10 Years
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 3 and ≤ 10 years of age * Healthy and not suffering from any physical disability. * Height-for-age and BMI-for-age between the 5th and the 95th percentile as well as a weight-for-age between the 5th and the 85th percentile * Consumption of 2 servings/day of the investigational product for 7 consecutive days * Willingness to follow the study procedures and record the data in the diary and complete any forms or assessment as needed throughout the study * Agreement to not consume a nutritional product that is not study product during the study period
Exclusion criteria
* History of an acute or chronic condition that may affect feeding habits or nutritional status * Medications or nutritional supplements, taken on a daily basis for more than 2 weeks during the past month prior to screening visit that may profoundly affect feeding habits or nutritional status * Clinically significant nutritional deficiency requiring specific treatment * Acute/chronic condition requiring medical treatment which may include hospitalization such as diabetes or stress induced hyperglycemia, dialysis treatment, inflammatory bowel disease, pancreatitis, autoimmune disease or immunodeficiency, celiac disease, cystic fibrosis, active tuberculosis, malformation of the gastrointestinal tract or gastroesophageal reflux disease * History of constipation * Allergy or intolerance to any ingredient in the study product * Gastrointestinal infection or acute diarrhea at the time of study start * Hepatitis B or C, or HIV, or malignancy * Congenital cardiac defects * Antibiotic therapy within last 2 weeks of start of study * Dysphagia, aspiration risk, difficulty in swallowing due to acquired/congenital abnormalities
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gastro-Intestinal Tolerance | Study Day 1-7 | Self-reported Questionnaire |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Study Supplement Compliance | Study Day 1-7 | Self-reported number of servings consumed per day |
| Weight | Study Day 1 and 8 | — |
| Height | Study Day 1 and 8 | — |
Countries
United States
Outcome results
None listed